Reneo Pharmaceuticals Incorporated develops therapies for patients with rare genetic mitochondrial diseases. REN001 is a selective peroxisome proliferator-activated receptor delta agonist in (1) Phase IIb clinical trials in patients with primary mitochondrial myopathies, and (2) Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals was incorporated in 2014 and is headquartered in San Diego, CA.
What is Reneo Pharmaceuticals's quote symbol?
What is the 52 week high and low for Reneo Pharmaceuticals (NASDAQ: RPHM)?
How much is Reneo Pharmaceuticals stock worth today?
How much is Reneo Pharmaceuticals's stock price per share?
What is Reneo Pharmaceuticals's Market Cap?